This study was presented as a scientific abstract in poster form at the 2011 ACVIM Forum, Denver, CO
Efficacy of Low- and High-Dose Trilostane Treatment in Dogs (< 5 kg) with Pituitary-Dependent Hyperadrenocorticism
Article first published online: 20 NOV 2012
Copyright © 2012 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 27, Issue 1, pages 91–98, January/February 2013
How to Cite
Cho, K.-D., Kang, J.-H., Chang, D., Na, K.-J. and Yang, M.-P. (2013), Efficacy of Low- and High-Dose Trilostane Treatment in Dogs (< 5 kg) with Pituitary-Dependent Hyperadrenocorticism. Journal of Veterinary Internal Medicine, 27: 91–98. doi: 10.1111/jvim.12007
- Issue published online: 11 JAN 2013
- Article first published online: 20 NOV 2012
- Manuscript Accepted: 25 SEP 2012
- Manuscript Revised: 25 JUL 2012
- Manuscript Received: 14 MAY 2012
- Ministry of Education, Science and Technology. Grant Number: 2011-0031403
- Adrenocorticotropic hormone;
- Cushing's disease;
Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH.
To compare the efficacy of 2 trilostane protocols in the treatment of dogs with PDH.
Sixteen client-owned dogs with PDH and a body weight <5 kg.
Prospective observational study. Group A (n=9; low-dose treatment group) received 0.78 ± 0.26 mg of trilostane/kg PO every 12 h and group B (n = 7; high-dose treatment group) 30 mg of trilostane/dog PO every 24 h. All of the dogs were reassessed at 2, 4, 8, 12, 16, and 24 weeks after the initiation of treatment.
An improvement in both ACTH-stimulated serum cortisol concentrations and clinical signs occurred more slowly in group A than in group B; however, after 20 weeks of treatment, 2/7 dog in group B had clinical signs and abnormal laboratory findings consistent with hypoadrenocorticism. At 24 weeks, an improvement in the clinical findings of all of the dogs in both groups was detected.
Conclusions and clinical importance
In dogs with PDH, twice-daily administration of low-dose trilostane is an effective approach to the management of PDH. In addition, our results suggest fewer potential adverse effects if trilostane is administered twice daily in the lower dose.